$SILO News

SILO Pharma Q1 EPS $(0.12) Up From $(0.23) YoY, Sales $18.026K, Same YoY

Silo Pharma Launches Ibogaine-Based TBI Drug Initiative, Files Patent Amid Growing Psychedelic Therapy Push

Silo Pharma shares are trading lower after the company announced the acquisition of Qwikagents.ai.

Silo Pharma shares are trading lower after the company announced the acquisition of Qwikagents.ai.

Silo Pharma shares are trading lower after the company announced the acquisition of Qwikagents.ai.

Silo Pharma Expands Into Multi-Billion Dollar AI Agent Market with Acquisition Of Managed AI Agent Platform, Qwikagents.ai

Silo Pharma Highlights Pipeline Strength Amid Rising U.S. Policy Focus On Psychedelic Mental Health Treatments.

Silo Pharma Rallies After Securing Key Patent Allowance

Silo Pharma shares are trading higher after the company announced that the European Patent Office intends to grant a patent for an application titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress"

Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know

Silo Pharma shares are trading higher after the company announced that the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress"

Silo Pharma Secures European Patent Office Nod For Columbia‑Licensed Stress Therapy Using Serotonin 4 Receptor Agonists

Silo Pharma shares are trading higher after the company announced a $1 million buyback.

Silo Pharma shares are trading higher after the company announced a $1 million buyback.

Silo Pharma Announces $1M Buyback Plan

Silo Pharma Gets Notice Of Allowance From Japan Patent Office For Patent Application Covering SPC-15

Silo Pharma Signs Non-Binding Letter Of Intent With Allucent To Offer Clinical Research Services For Two Phase 1 Trials Of SPC-15 Nasal Spray

Silo Pharma Selects Allucent To Support Preparations And Planned Submission Of IND For Phase 1 Trial Of SPC-15 As A Therapeutic For PTSD

Silo Pharma Selects The Alphaledger/Simplify Target 12% Distribution Fund As Part Of Its Real-World Asset Investment Strategy On The Solana Blockchain

Silo Pharma Provides Update On Lead PTSD Candidate, SPC-15, Highlighting Safety And Toxicology Results, Ind-Enabling Studies, And Expanded Patents In The U.S., Australia, And Japan. Company Also Launched A Digital Assets Treasury In August 2025, Acquiring Bitcoin, Ethereum, Solana, And ResearchCoin